Results 241 to 250 of about 59,185 (303)
Some of the next articles are maybe not open access.

Recombinant Zoster Vaccine (Shingrix®): A Review in Herpes Zoster

Drugs & Aging, 2018
Shingrix® is a recombinant zoster vaccine (RZV) that contains a varicella zoster virus glycoprotein E antigen and the AS01B adjuvant system. The subunit vaccine is approved for the prevention of herpes zoster (HZ) [EU, USA, Japan, Canada and Australia] and postherpetic neuralgia (PHN) [EU and Australia] in adults aged ≥ 50 years.
Yahiya Y. Syed
openaire   +3 more sources

Increased Stroke Risk Following Herpes Zoster Infection and Protection with Zoster Vaccine.

Clinical Infectious Diseases, 2022
BACKGROUND Studies evaluating stroke following varicella zoster infection are limited, and the utility of zoster vaccination against this phenomenon is unclear. PURPOSE To determine the risk of stroke 30 days following zoster infection, and to evaluate
G. Parameswaran   +8 more
semanticscholar   +1 more source

Herpes Zoster Following COVID-19 Vaccination

Journal of Drugs in Dermatology, 2021
Vaccination is an important intervention in preventing the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Messenger RNA (mRNA) vaccines from Pfizer™ and Moderna™ are the first to market in the United States, and while cutaneous adverse events have been reported in clinical trials for both of these vaccines, they ...
Eden, David, Angelo, Landriscina
openaire   +2 more sources

Recombinant Zoster Vaccine (Shingrix) to Prevent Herpes Zoster

Nursing for Women's Health, 2018
Women ages 50 years and older are at risk for herpes zoster, a reactivated virus from varicella zoster virus (chickenpox) that causes a painful vesicular rash and can result in postherpetic neuralgia. It is estimated that one in three adults will be affected by herpes zoster in their lifetime.
Jacqueline R. Sly, Allyssa L. Harris
openaire   +2 more sources

Home - About - Disclaimer - Privacy